WHY CHOOSE PURAPLY®AM

Early bioburden management with PuraPly AM following sharp debridement empowers you to take immediate command of the healing environment.1-6

PURAPLY AM OVERVIEW

Examine how PuraPly AM combines native, cross-linked ECM + broad-spectrum PHMB to provide a sustained antimicrobial barrier to control bioburden and biofilm re-formation.5,6 Also, read various perspective papers on the importance of managing biofilm.

LEARN MORE 

PURAPLY AM PRODUCT DETAILS

View the wound types that PuraPly AM can manage and the available product sizes. Also, see how to apply PuraPly AM.

LEARN MORE 

CONFIRMATION OF CONTROL

Discover the clinical and real-world evidence that demonstrates the effectiveness of PuraPly AM, or contact an Organogenesis Tissue Regeneration Specialist to see how PuraPly AM can help your practice.

Contact us

REFERENCES:

  1. Hübner NO, et al. Skin Pharmacol Physiol. 2010;23(1 suppl):17-27.
  2. Brantley J, et al. Wounds Int. 2016;7(3):1-5.
  3. Gilbert P, et al. J Appl Microbiol. 2005;99(4):703-715.
  4. Data on file. PDR-0001. Organogenesis Inc.
  5. Data on file. PDR-0002. Organogenesis Inc.
  6. PuraPly Antimicrobial [package insert]. Canton, MA: Organogenesis Inc; 2020.